BRAF and neoplasm: Nevertheless, with objective response rates of 60–70%, the majority of patients with BRAF mutant melanoma respond to MAPK inhibitors, and if we are to improve progression‐free survival in these patients, it is of paramount importance to understand the biology of the responding tumours before and on treatment.